AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech(AIM) Newsfilter·2024-01-24 22:10公司介绍 - AIM ImmunoTech Inc.是一家专注于研发治疗多种癌症、免疫紊乱和病毒性疾病的免疫药物公司[4] 临床试验详情 - AMP-270是一项随机、开放标签、对照、平行臂临床试验，旨在比较Ampligen与无治疗对照组在FOLFIRINOX后对局部晚期胰腺腺癌患者的疗效[2] 欧洲地区试验授权 - AIM ImmunoTech Inc.宣布获得Erasmus Medical Center伦理委员会授权，开设欧洲地区的AMP-270临床试验[1]